Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
- S. Harland, D. Newell, Z. Siddik, R. Chadwick, A. Calvert, K. Harrap
- Biology, MedicineCancer Research
- 1 April 1984
In vitro studies with plasma and urine demonstrated that, in contrast to cisplatin, CBDCA is a stable complex [t 1/2 - 37 degrees; plasma, 30 hr, and urine, 20 to 460 hr].
A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice.
- T. R. Jones, A. Calvert, A. Jackman, S. Brown, M. Jones, K. Harrap
- Biology, ChemistryEuropean Journal of Cancer
- 1981
Changes in the deoxyribonucleoside triphosphate pools of mouse 5178Y lymphoma cells following exposure to methotrexate or 5-fluorouracil.
- M. Tattersall, K. Harrap
- Chemistry, MedicineCancer Research
- 1 December 1973
Changes are reported in the deoxyribonucleoside triphosphate pools of L5178Y cells during their exposure to methotrexate or 5-fluorouracil, accompanied by an increase in deoxycytidine triph phosphate concentration.
Studies with a mathematical model of folate metabolism.
- R. Jackson, K. Harrap
- BiologyArchives of Biochemistry and Biophysics
- 1 October 1973
ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer.
- A. Jackman, D. Farrugia, F. T. Boyle
- Biology, MedicineEuropean journal of cancer
- 1 July 1995
Biotransformation of the platinum drug JM216 following oral administration to cancer patients
- F. Raynaud, P. Mistry, K. Harrap
- Chemistry, BiologyCancer Chemotherapy and Pharmacology
- 1996
The biotransformation profile following oral administration of JM216 shows a variety of Pt(IV) and Pt(II) metabolites in plasma that differ significantly from other systemically applied platinum drugs.
A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration
- M. McKeage, P. Mistry, I. Judson
- Medicine, BiologyCancer Chemotherapy and Pharmacology
- 2004
Clinical studies of divided dose schedules using doses within the range of pharmacokinetic linearity (≤120 mg/m2) are now being investigated and little nonhaematological toxicity was seen at doses associated with myelosuppression and antitumour activity.
Genomic imbalances associated with acquired resistance to platinum analogues.
- B. Leyland-Jones, L. Kèlland, K. Harrap, L. Hiorns
- BiologyThe American journal of pathology
- 1 July 1999
Studies on the pharmacokinetics of chlorambucil and prednimustine in man.
- D. Newell, A. Calvert, K. Harrap, T. Mcelwain
- Biology, ChemistryBritish journal of clinical pharmacology
- 1 February 1983
Research aimed at producing chlorambucil analogues, which cannot be metabolised, seems justified, and the use of prednimustine in routine combination therapy is not recommended.
...
...